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ABSTRACT
Protein kinase CK2α, one of the two catalytic isoforms of the protein kinase 
CK2 has been shown to contribute to tumor development, tumor proliferation and 
suppression of apoptosis in various malignancies. We conducted this study to 
investigate CK2 expression in different subtypes of Renal Cell Carcinoma (RCC) 
and in the benign oncocytoma. qRT-PCR, immunohistochemistry and Western blot 
analyses revealed that CK2α expression was significantly increased at the mRNA 
and protein levels in clear cell RCC (ccRCC). Also the kinase activity of CK2 was 
significantly increased in ccRCC compared to normal renal cortex. Nuclear protein 
expression of CK2α correlated in univariate analysis with poor Progression Free 
Survival (HR = 8.11, p = 0.016). Functional analyses (cell proliferation assay) 
revealed an inhibitory effect of Caki-2 cell growth following CK2 inhibition with 
CX-4945. Our results suggest that CK2α promotes migration and invasion of ccRCC 
and therefore could serve as a novel prognostic biomarker and molecular therapeutic 
target in this type of cancer.
INTRODUCTION
Renal cell carcinoma (RCC) is the most lethal of 
the common urological cancers with 338.000 new cases 
and 144.000 deaths registered worldwide in 2012 [1]. 
RCC comprises a heterogeneous group of neoplasms, 
and according to WHO, it is classified into four main 
histological subtypes based on morphology and genetics 
[2]. The most frequent subtype is the clear cell renal cell 
carcinoma (ccRCC), which comprises 75-80% of all 
RCCs. The papillary carcinoma (PRCC, 10% of RCC), 
chromophobic carcinoma (ChRCC, 5% of RCC) and 
collecting duct carcinoma (2% of RCC) are the other 
main subtypes. The benign tumor, renal oncocytoma (RO), 
comprises 3-5% of all adult renal tumors [3].
Widely used clinicopathological parameters, such as 
TNM staging and nuclear Fuhrman grade, provide robust 
prognostic information. However, they cannot accurately 
predict a reliable outcome for RCC since similar TNM 
stage and nuclear grade may have very different outcomes. 
One third of patients has metastases at diagnosis and 
among those with clinically localized disease, 30-40% will 
develop metastases after surgery [4]. Identifying this high-
risk group of RCC patients remains a challenge. RCC is 
often late diagnosed and has a poor response to available 
therapies. Therefore, there is a clear need for markers that 
can predict outcome in RCC patients or guide treatment 
decisions.
Inactivation of the VHL tumor suppressor gene is 
observed in all inherited forms of RCC and in many of the 
sporadically occurring tumors [5]. Despite the role of VHL 
in the hypoxia pathway of the RCC pathogenesis it can be 
expected that also other genetic alterations are necessary 
for tumor formation [6]. Accordingly, there is a very active 
search for new biomarkers in the field of renal oncology 
that have the potential to further improve diagnosis, 
treatment and prognosis of RCC. Despite the efforts, 
known biomarkers did not advance to clinical routine [7].
Protein kinase CK2 is a multifunctional, 
ubiquitously expressed protein kinase with a large array 
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of more than 300 substrates. Many of these are critically 
involved in the regulation of cell growth, proliferation 
and differentiation [8-11]. These include oncogenes, 
transcription factors and tumor-suppressor genes as well 
as proteins involved in signal transduction pathways. 
Increasing evidence indicates that CK2 is linked to cellular 
transformation and cancer [12, 13]. For instance, high 
levels and protein kinase activity of CK2 have consistently 
been observed in a variety of cancers, including kidney 
[14], breast [15], colorectal [16], head and neck cancers 
[17] and glioblastoma [18]. Overexpression and prognostic 
significance of CK2α subunit have been observed in lung 
cancer, prostate cancer, and leukemia [19-21].
The kinase has a tetrameric structure of the catalytic 
subunits, α and α’, and the regulatory β subunit with an 
α2β2, αα’b2 or α’2β2 configuration and is localized in both 
the nucleus and cytosolic subcellular compartments [22]. 
Not only the holoenzyme, but also the isolated catalytic 
subunits are active and can exert independent functions 
in cells [23].
In a previous study we could show that high mRNA 
expression of CK2α was associated with poor prognosis in 
ccRCC [24]. However, the detailed prognostic and functional 
role of CK2α in human RCC is still to be explored.
The aim of this study was to investigate mRNA 
expression of the different subunits of CK2 in ccRCC, 
protein levels of CK2α in different subtypes of RCC 
and in renal oncocytoma and to evaluate the prognostic 
value of protein expression of CK2α in ccRCC patients. 
Additionally, we aimed at verifying whether chemical 
inhibition of CK2 affected proliferation of human cancer 
cells lines in vitro.
RESULTS
Patient characteristics
We examined a total of 155 patients with different 
subtypes of RCC and oncocytoma. There were 94 males 
and 61 females with a mean age of 61.9 years (range 28.1-
86.4). The mean tumor size was 6.73 cm (range 1.5-22). 
Clinical and demographic data for all patients included are 
summarized in Table 1.
Overexpression of CK2α in human ccRCC
Quantitative RT-PCR data from 97 ccRCCs were 
generated from another study [24]. In addition, qRT-PCR 
data were generated for 23 PRCC, 8 ChRCC and 11 RO 
for the purpose of this study. CK2α was expressed 1.87 
fold higher in the tumor tissue of ccRCC than normal 
renal cortex (p < 0.0001). (Figure 1A). No statistically 
significant difference was observed between the different 
subtypes of RCC, RO and the subunits of CK2, Figure 
1B-1D. The correlation of mRNA expression of the 
different CK2 subunits in ccRCC to Fuhrman grade, tumor 
stage and metastasis showed a significant higher CK2α 
expression in high Fuhrman grade (p=0.001), high tumor 
stage (p=0.007) and a tendency towards a higher rate of 
metastasis (p=0.07), Figure 2A. High mRNA expression 
of CK2α’ correlated to a low Fuhrman grade (p= 0.01), 
Figure 2B. Messenger RNA expression of CK2β did 
not correlate with any of the clinicopathological factors, 
Figure 2C.
Nuclear localization of CK2α correlates to 
metastatic rate
Immunohistochemistry for CK2α was carried out on 
all 155 cases of renal cell neoplasms using TMA. Nine 
cores containing normal renal cortex were lost in the 
processing. CK2α was strongly expressed in 19 (18%) 
ccRCCs, 5 PRCCs (19%), 1 ChRCC (13%) and 4 ROs 
(30%) (Table 2). Strong expression was defined as a score 
of >2+ when a sum of nuclear and cytoplasmic staining 
was made (Figure 3). A positive nuclear staining was 
found in 75% of ccRCC, 67% of PRCC, 87% of ChRCC 
and 92% of RO, respectively. No difference was found 
between normal renal cortex and ccRCC (Fisher’s exact 
test, p = 0.4).
The expression of CK2α in high stage ccRCC 
(pT3-4) was compared with gender, age, Fuhrman grade, 
tumor size, Leibovich score, T-stage, metastasis and VHL 
mutation status. A positive nuclear staining of CK2α 
correlated significantly with late metastasis (Table 3). We 
performed a Kaplan Meier survival analysis on ccRCC 
patients with a high pathological stage (pT3-4). There was 
a statistically significant correlation between the Nuc+ 
expression group (log-rank, p=0.02, HR = 8.11) and poor 
PFS and a tendency toward a correlation with DSS (log 
rank p=0.06, HR = 5.6) (Figure 4). In a multivariate cox 
regression analysis including the 40 patients with high 
stage ccRCC and the variables CK2α nuclear expression, 
Fuhrman grade G1-G2/G3-G4, tumor size <7/≥7 cm, VHL 
mutation and gender, nuclear expression of CK2α lost its 
prognostic value (Table 4).
Western blotting and CK2 kinase activity
Kinase activity of CK2 was significantly higher 
in the ccRCC samples compared to normal renal cortex, 
p = 0.03 (Figure 5A). To validate the IHC results, we 
performed an analysis of CK2α protein expression by 
Western blotting in a subset of 6 ccRCC samples together 
with normal renal cortex. As shown in Figure 5B-5C, 
CK2α protein expression was significantly higher in the 
tumor tissue compared to normal renal cortex.
Proliferation assay
In order to investigate whether CK2α could 
also be a therapeutic target of ccRCC, we evaluated 
Oncotarget1615www.impactjournals.com/oncotarget
Table 1: Clinical and demographic data of the 155 patients included in the TMAs.
ccRCC (n=105) PRCC (n=27) ChRCC (n=8) RO (n=13) UcRCC (n=2)
Sex
Male 60 (57) 22 (81.5) 5 (62.5) 6 (46.2) 1 (50)
Female 45 (43) 5 (18.5) 3 (37.5) 7 (53.9) 1 (50)
Age, years 62.2 (range 28.1-86.4) 61.2 (range 28.4-81.0) 51.5 (range 38.6-63.9) 66.2 (range 39.5-81.5) 70.5 (range 69.6-71.4)
Tumor size, cm 7.2 (range 2-22) 5.0 (range 1.5-11) 7.4 (range 3.7-11.5) 5.6 (range 2.2-15) 10.5 (8-13)
pT stage §
pT1 a/b 43 (41) 17 (65.4) 2 (25) . 0
pT2 a/b 22 (21) 3 (11.5) 3 (37.5) . 1 (50)
pT3 a/b 39 (37) 5 (19.2) 3 (37.5) . 1 (50)
pT4 1 (1) 1 (3.9) 0 (0) . 0
Late metastasis 32 (30.5) 6 (22.2) 0 (0) . 1 (50)
Fuhrman grade
G1 6 (5.7) 0 (0) 0 (0) . 0 (0)
G2 51 (48.6) 17 (63) 1 (12.5) . 0 (0)
G3 37 (35.2) 10 (37) 4 (50) . 2 (100)
G4 11 (10.5) 0 (0) 3 (37.5) . 0 (0)
Leibovich score#
0-2 30 (33) . . . .
3-5 39 (43) . . . .
≥ 6 22 (24) . . . .
§Missing information on one patient. #Only patients with non-metastatic RCC at the time of diagnosis was assigned a Leibovich score (n=91). The table 
specifies numbers (%) for categorical variables and mean (range) for continuous variables. Abbreviations: ccRCC (clear cell Renal Cell Carcinoma), PRCC 
(Papillary Renal Cell Carcinoma), ChRCC (Chromophobic Renal Cell Carcinoma), RO (Renal Oncocytoma), UcRCC (Unclassifiable Renal Cell Carcinoma).
Figure 1: A. Relative gene expression levels of the CK2 subunits α, α’ and β by qRT-PCR showing a significantly higher expression in 
ccRCC than matched normal renal cortex. B-C. Gene expression levels of the three CK2 subunits in different subtypes of RCC (ccRCC, 
clear cell renal cell carcinoma; PRCC, papillary renal cell carcinoma; ChRCC, chromophobe renal cell carcinoma) and in the benign 
oncocytoma (Onco). No significant difference was found.*** p< 0.001, ****p< 0.000.
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the effects of two CK2 inhibitors (CX-4945 10 μM 
and E9 50 μM) on proliferation of Caki-2 cells using 
a colorimetric assay. Cells proliferated in a time-
dependent fashion regardless of the treatment. However, 
CX-4945 significantly inhibited the proliferation of 
Caki-2 cells compared to vehicle-treated controls 
(Figure 6A and 6C, 49 % of control at confluence 
(*indicates p<0.01 vs. vehicle)). Figure 6B shows 
protein expression of CK2α by Western blot analysis 
in Caki-2 lysates and HepG2 cells not treated with 
CX-4945. E9 did not inhibit Caki-2 cell proliferation 
(Supplementary Figure S1).
DISCUSSION
In a study done previously by our group, we 
discovered that high CK2α mRNA expression correlated 
with poor overall survival, disease specific survival and 
progression free survival in patients with ccRCC [24]. In 
this study our aim was to investigate the impact of a high 
protein expression of CK2α on survival of patients with 
ccRCC and furthermore, mRNA and protein expression 
of CK2 in the different subtypes of RCC and oncocytoma.
Protein kinase CK2α is one of the two isoforms 
of the catalytic subunit of the protein kinase CK2 and is 
Figure 2: Relative gene expression levels of the three CK2 subunits and their correlation to clinicopathological factors. 
A. High expression of CK2α correlates to high Fuhrman grade (p=0.001), high stage (p=0.007) and distant metastasis (p=0.07). B. High 
expression of CK2α’ correlates to low Fuhrman grade (p=0.01). C. Expression of CK2β did not correlate to any of the clinicopathological 
factors.
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overexpressed in various malignancies. Previously it has 
been shown that protein kinase CK2 activity in kidney 
cancer is higher compared to normal renal cortex [14], but 
the association between CK2α and clinicopathological 
features or prognosis in RCC remains unknown. In the 
present study, we assessed mRNA expression of CK2α, 
α’ and β subunits and protein expression levels of 
CK2α subunit in different subtypes of RCC (clear cell, 
papillary and chromophobic) and in the benign renal 
tumor, oncocytoma. Messenger RNA expression of all 
CK2 subunits was significantly up-regulated in tumor 
tissue of ccRCC compared to renal cortex. In addition, 
high mRNA expression of CK2α correlated with poor 
prognostic markers (high Fuhrman grade, high stage and 
late metastasis), whereas high mRNA expression of CK2α’ 
correlated with good prognosis. At protein level, a positive 
CK2α staining in the nuclei was associated with poor PFS 
in the patient group with high stage cancer. We found a 
higher protein expression in the ccRCC tissue compared 
to normal renal cortex by western blotting and in addition, 
a higher kinase activity in the tumor.
The catalytic subunits of CK2 are known to exert a 
significant protective effect against apoptosis, whereas the 
β-subunit does not induce a comparable effect [25]. The 
subunits of CK2 can exist in a dissociated form in the cell 
and in different compartments. Hence, their localization 
in specific cellular regions might represent a mode of 
functional regulation of CK2 that affects cell survival [26]. 
Our results indicate that CK2α is highly expressed at both 
mRNA and protein levels. The protein is mainly localized 
in the nucleus and its expression has a negative impact 
on prognosis. Findings reported here, support the notion 
that the individual CK2 subunits might exert functions 
independent from the holoenzyme as previously reported.
Laramas et al provided evidence for a strong 
association between nuclear expression of CK2α and poor 
prognostic factors in human prostate cancer [19]. However, 
they did not show any correlation between cytoplasmic 
staining and poor prognosis. Our findings are consistent with 
this study, in which only the nuclear overexpression of CK2α 
was found to have an adverse effect on prognosis. In a minor 
study by Roelants et al, the expression and enzymatic activity 
of the CK2 subunits were investigated in 15 patients with 
RCC [27]. They could show that the CK2α and α’ subunits 
were overexpressed at protein level and it correlated with 
an enhanced CK2 kinase activity. These findings are very 
similar to the findings of our study. However, at mRNA 
level, a strong downregulation of these subunit transcripts 
in tumor samples compared with normal tissues was found, 
contradictory to what we discovered in our mRNA studies. 
There could be several reasons for this discrepancy. First 
of all, we included more than 100 patients with the ccRCC 
subtype and second of all, we used other reference genes for 
normalization. They furthermore analyzed the importance 
of CK2 activity on the proliferation of renal cancer cells in 
786-O RCC cells (786-O WT) or isogenic 786-O cells either 
reconstituted with functional VHL (786-VHL) or expressing 
the empty expression vector pBABE (786-O pB) and 
exposed them for increasing concentrations of CX-4945. The 
growth of all three cell lines was inhibited in a concentration-
dependent fashion. This is in accordance with the results 
obtained in our study.
The basic mechanisms behind the association 
between an unfavorable prognosis and high CK2 expression 
are still being explored. CK2 regulates multiple pathways 
including PI3K/Akt and WNT signaling cascades, NF-
κB transcription, and the DNA damage response [12, 28]. 
Several functions of CK2 have been identified through 
which high CK2 activity favors neoplastic growth; it 
enhances the transforming potential of oncogenes [29], it 
supports neovascularization [30], it potentiates the multi-
drug resistance phenotype [31], and it generates abnormal 
pro-survival and anti-apoptotic signals [32]. In addition, it 
has been shown that inhibition or down-regulation of CK2 
Table 2: Protein expression of CK2α in renal epithelial neoplasms with TMA.
Renal 
neoplasm
CK2α (0) CK2α (1-2+) CK2α (3-5+) p-value CK2α Nuc-
(0)
CK2α Nuc+ 
(1-4+)
p-value
ccRCC 
(n=105) 25 (24%) 61 (58%) 19 (18%)
0.6
26 (25%) 79 (75%)
0.4
PRCC (n=27) 9 (33%) 13 (48%) 5 (19%) 9 (33%) 18 (67%)
ChRCC (n=8) 1 (13%) 6 (74%) 1 (13%) 1 (13%) 7 (87%)
RO (n=13) 1 (8%) 8 (62%) 4 (30%) 1 (8%) 12 (92%)
UcRCC (n=2) 0 (0%) 1 (50%) 1 (50%) 0 (0%) 2 (100%)
Renal cortex 
(n=146) 4 (3%) 129 (88%) 13(9%) 4 (3%) 142 (97%)
Abbreviations: CK2α, protein kinase 2 alpha subunit; TMA, tissue microarray; ccRCC, clear cell renal cell carcinoma; 
PRCC, papillary renal cell carcinoma; ChRCC, chromophobe renal cell carcinoma; RO, renal oncocytoma, UcRCC, 
unclassifiable RCC; Nuc, nuclear staining of CK2α.
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Figure 3: Tissue micro arrays including ccRCC (n=105), PRCC (n=27), ChRCC (n=8), UcRCC (n=2), RO (n=13) and 
normal renal cortex (n=146) were immunohistochemically stained for CK2α. Stainings were evaluated semi-quantitatively 
with the following scores: the extent of staining of moderate to strong intensity in the nuclei was scored as 0 (0%), 1+ (1-25%), 2+(26-50%), 
3+(51-75%) or 4+(76-100%) according to the percentages of the positive staining areas relative to the entire core area. The cytoplasm was 
scored as 0 or 1+, when more than 10% of the cytoplasm area showed positivity. The sum of nuclei and cytoplasm was used as the final 
CK2α score (0-5+). A-D. High protein expression of CK2α (3-5+) in ccRCC (5+), ChRCC (4+), PRCC (3+) and oncocytoma (4+). E-H. 
Representative stainings of CK2α in ccRCC. Scalebar indicates 0-250 μm. 400x magnification.
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leads to apoptosis in several cancer cell lines [33-36]. CK2 
has been shown to regulate PI3K/Akt signaling at multiple 
junctions along the signaling cascade including the Akt 
protein [12]. PI3K/Akt signaling is known to regulate the 
response of endothelial cells to growth factor signaling 
including proliferation, migration and tube formation [37] 
and represents thereby a molecular mechanism through, 
which CK2 can drive angiogenesis. Another mechanism 
by which CK2 may contribute to angiogenesis is through 
regulation of HIF-1α. HIF-1α is often highly active in renal 
cell carcinoma due to mutations in VHL and subsequently 
accumulation of HIF-1α. Hypoxia increases the activity of 
CK2 and elevated CK2 activity results in the up-regulation 
of HDAC1/HDAC2 histone deacetylases that inhibit the 
expression of tumor suppressor genes pVHL and p53, 
thereby increasing HIF-1α [38]. HSP-90 regulates a VHL–
independent HIF-1α degradation pathway. During hypoxia, 
HIF-1α associates with HSP90 and becomes stabilized. 
HSP90 and its co-chaperone Cdc37 are also substrates 
for protein kinase CK2 [39]. A comprehensive study 
investigating the signaling pathways of CK2 in renal cancer 
was beyond the scope of this study. However, Roelants et al 
did show that CX-4945 inhibited phosphorylation of AKT, 
p21 and α-catenin in renal cancer cell lines and moreover, 
they could show that CX-4945-induced p38MAPK 
activation correlated with increased p53 expression [27].
It has also been shown that an inverse relationship 
between promyelotic leukemia protein (PML) and CK2 
activity exists and that PML degradation upon CK2 activation 
can account for the frequent loss of PML expression observed 
in multiple human tumors [12]. PML is a nuclear-matrix-
associated protein and specifically a nuclear accumulation 
of CK2α could therefore be functionally relevant in order to 
inactivate the tumor-suppressive functions of PML [19].
Table 3: High stage ccRCC patient characteristics and protein expression of CK2α (n=40).
ccRCC Patients (%) CK2α (0-2+) CK2α (3-5+) p-value Nuc - Nuc + p-value
Sex
Male 24 (60) 21 3 8 16
Female 16 (40) 13 3 0.59 1 15 0.044*
Age§
≤ 64 20 (50) 16 4 5 15
> 64 20 (50) 18 2 0.38 4 16 0.7
Fuhrman
G1+G2 17 (42.5) 13 4 5 12
G3+G4 23 (57.5) 21 2 0.19 4 19 0.37
Tumorsize§
< 7 16 (40) 12 4 5 11
≥ 7 23 (57.5) 21 2 0.17 4 19 0.31
Leibovich 
score#
0-2 0 (0) 0 0 0 0
3-5 15 (37.5) 11 4 4 11
≥ 6 15 (37.5) 14 1 0.14 4 11 1.0
Late 
metastasis
No 21 (52.5) 17 4 8 13
Yes 19 (47.5) 17 2 0.45 1 18 0.013*
VHL mutation
No 25 (62.5) 23 2 5 20
Yes 15 (37.5) 11 4 0.11 4 11 0.63
§: missing information on one patient. * p <0.05. #Only patients with non-metastatic RCC at the time of diagnosis was assigned 
a Leibovich score (n=30).
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In this study, the relationship between both a high 
mRNA expression and a positive nuclear expression of 
CK2α and distant metastasis suggested that increased 
expression of CK2α might accelerate the migration 
and invasion of tumor cells. To illustrate the potential 
mechanisms of CK2α in proliferation of tumor cells, 
we performed in vitro functional studies testing two 
different selective inhibitors of CK2 in predetermined 
concentrations [38, 40, 41].
We investigated the impact of CX-4945 and E9 on 
Caki-2 cell growth. The CK2 inhibitor CX-4945 exhibits 
anticancer activity by down-regulation of PI3K/Akt, p21 and 
HIF-1α and by that affects the transcriptional regulation of 
factors involved in cancer proliferation, angiogenesis and 
pro-inflammatory cytokine production. CK2 inhibition results 
in apoptotic cell death in tumor cells [42]. We also tested E9, 
which is a novel highly selective CK2 inhibitor. E9 leads to 
the degradation of HIF-1α during hypoxia and reduces the 
activation of ERK, which controls diverse cellular processes 
such as proliferation, survival and differentiation [38]. In our 
study we observed a significant reduced proliferation of the 
cells treated with CX-4945 compared to vehicle (reduced to 
49% of control), whereas the cells treated with E9 grew in 
almost same density as vehicle. In a study by Guerra et al 
the efficacy of E9 on inhibition of CK2 was investigated in 
several cell lines, including a human renal carcinoma cell line 
(Cal54) [38]. They could show that some cell lines were more 
prone to E9 inhibition in comparison to others. E9 inhibited 
Cal54 and PC3 (human prostate cancer) to a less extent than 
Wit49 (Wilm’s tumor), HepG2 (human hepatoma), Panc-
1 (human pancreatic carcinoma) and Mia-Paca-2 (human 
pancreatic carcinoma). Also PARP cleavage analysis by 
Western blotting investigating the induction of apoptosis 
by E9 showed significant differences among the cell lines 
with no significant PARP cleavage detected in Cal54, Wit49 
and PC3 cells. The different response in cell proliferation 
by treatment with CX-4945 and E9 in our study might be 
caused by distinct and/or unrelated intracellular targets of the 
two inhibitors. An unevenly CK2 inhibition by the chosen 
concentrations of CX-4945 and E9 could be another reason.
Figure 4: Nuclear staining of CK2α was correlated to overall survival (OS), disease specific survival (DSS) and 
progression free survival (PFS) in 40 patients with ccRCC high stage disease (pT3-4). Nuc- was defined as 0 (0%) positive 
nuclei. Nuc+ was defined as 1-4 (1-100%) positive nuclei. A. No association to OS was found. B. A tendency towards a poor DSS was seen 
(HR = 5.6, p = 0.06). C. A positive nuclear staining of CK2α was associated to a poor PFS (HR = 8.11, p=0.016).
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Table 4: Multivariate Cox regression analysis including clinical variables for high stage ccRCC (n=40) with 
Progression Free Survival as endpoint.
Variables Univariate 
analysis
Multivariate analysis
ccRCC p-value HR 95 % CI p-value
CK2α Nuc+ expression 0.043* 5.19 0.64-42.3 0.124
Fuhrman (G3+G4) 0.03* 4.79 1.41-16.28 0.012*
Tumorsize ≥ 7 cm 0.21 2.57 0.81-8.2 0.111
Female 0.07 3.42 1.05-11.07 0.04*
VHL mutation 0.64 1.24 0.45-3.45 0.68
* p <0.05
Figure 5: A. Whole cell lysates from normal (Renal cortex) and tumor (ccRCC) tissue samples (30 μg) were subjected to CK2 kinase 
activity assay as described in the materials and methods. The activity is expressed as percentage of control (Renal cortex). B. 30 μg 
of whole cell lysates from control (C, renal cortex) and tumor (T, ccRCC) were subjected to SDS-polyacrylamide gel electrophoresis 
(PAGE). Separated proteins were transferred to polyvinylidene difluoride (PVDF) membrane by western blot. Proteins were visualized by 
probing the membranes with antibodies against CK2α and β-actin, respectively. C. Densitometric analysis of protein bands is expressed as 
percentage of control.
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In conclusion, our study revealed up-regulated CK2α, 
α’ and β expression levels in ccRCC tumor tissue compared 
to normal renal cortex, but only high expression of CK2α 
was associated to poor prognostic factors (high stage, high 
Fuhrman grade and distant metastasis). At protein level, 
nuclear localization of CK2α correlated to a poor PFS and 
to distant metastasis suggesting that CK2α contributes to 
migration and invasion of tumor cells. Proliferation studies 
revealed an inhibitory effect of CX-4945 on Caki-2 cell 
growth. Thus, inhibition of CK2 is a promising approach 
for ccRCC treatment in combination with other treatment 
modalities. All together, our results indicate that CK2α 
may serve as a candidate prognostic biomarker and a new 
therapeutic molecular target for ccRCC.
MATERIALS AND METHODS
Inclusion of patients
Two different patient cohorts were included in this 
study. A cohort for the purpose of generating quantitative RT-
PCR data (n = 139) and a larger cohort for the purpose of 
performing immunohistochemistry (n=155), consisting of the 
patients included in the first cohort and 16 additional patients. 
The first cohort consisted of: ccRCC (n=97), also included 
in a previous study done by our group [24] and additionally; 
PRCC (n=23), ChRCC (n=8) and RO (n=11). The second 
cohort consisted of: ccRCC (n=105), PRCC (n=27), ChRCC 
(n=8), RO (n=13) and unclassifiable RCC (UcRCC, n=2).
Figure 6: A. Caki-2 cells were treated with CX-4945 (10 μM) for 7 days. Experiments were repeated three times and data (absorption, 
ABS) were expressed as the means ± SEM of 3 replicates for each condition. Absorbance values were normalized to vehicle (DMSO). 
Student’s T-test was used for statistical comparison of data sets at any given time point. *p< 0.01 vs. Control (vehicle). B. Western blot 
analyses of CK2α in Caki-2 cell lysates and HepG2 not treated with CX-4945. HepG2 served as a positive control. Actin expression served 
as a loading control. C. Pictures showing Caki-2 cells at the seventh day of the proliferation assay. At day 7, vehicle (DMSO 0.1%) was 
confluent, while cells in the presence of CX-4945 (10 μM, right picture) show a reduction to 49%. The scale bar in each picture corresponds 
to 500 μm.
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Patient characteristics
We obtained frozen tumor tissue and normal renal 
cortex from 139 patients and paraffin-embedded tumor 
specimen and control tissue (healthy renal cortex) from 
the same 139 patients and additional 16 patients being 
nephrectomized because of either RCC or oncocytoma at the 
Odense University Hospital, Denmark, between 2001-2012. 
Prior patient consent and approval from the Danish Ethics 
Committee (notification number 29573, permit no. S-VF-
20010035, Region of Southern Denmark) and the Danish 
Data Protection Agency (file number 13/14405, permit no. 
2008-58-0035, Odense University Hospital) were obtained. 
Information concerning the date of initial diagnosis, clinical 
characteristics, relapse/metastasis and death were obtained 
retrospectively. The patients were followed up until death, 
last contact or censored on November 2015.
qRT-PCR
Quantitative RT-PCR data for the CK2 subunits, 
α, α’ and β (gene symbols CSNK2A1, CSNK2A2 and 
CSNK2B respectively) from 97 ccRCCs were generated 
using a Taqman Array and analyzed as described in detail 
in a previous study carried out by us [24]. See Table 5 for 
details on assay ID and gene reference sequence.
In brief, total RNA from frozen tumor and normal 
renal cortex samples was isolated using the TRIZOL 
reagent (Invitrogen, United Kingdom). First strand cDNA 
synthesis was carried out using the iScript cDNA Synthesis 
Kit (Bio-Rad, CA, USA). The Applied Biosystems 
TaqMan Array (custom-designed 384-well micro fluidic 
card with TaqMan Gene Expression Assay) was used to 
conduct the qRT-PCR study. All qRT-PCR were run in 
duplicate on an ABI PRISM 7900 HT Sequence detecting 
system (Applied Biosystems, Foster City, CA, USA). 
Tumor and cortex samples from the same patient were 
always run on the same plate.
qRT-PCR data were collected and evaluated with 
SDS 2.4 software (Applied Biosystems) and qBasePlus 
software (Biogazelle, Zwijnaarde, Belgium). TBP, 
PPIA and HMBS were used as reference genes and 
normalization was done using the qBasePlus software 
according to the modified Δ ΔCT method for multiple 
reference genes [43, 44].
Preparation of whole cell lysate, Western blot 
analysis and antibodies
Human frozen tissue samples from ccRCC 
and normal renal cortex (n=6) were re-suspended in 
lysis buffer [50mM Tris/HCl (pH 7.5), 150mM NaCl, 
1% Triton X-100, 10% glycerol, 1mM DTT, 1 mM 
Na3VO4, 30 mM β-glycerophosphate, 10 mM NaF, 
100 nM okadaic acid] containing a protease inhibitor 
cocktail (Roche, Switzlerland) and further processed as 
described elsewhere [45, 46]. The catalytic α-subunit of 
protein kinase CK2 was detected by probing the Western 
blot membrane with affinity-purified rabbit polyclonal 
anti-CK2α antibody obtained by immunizing rabbits 
with the full-length protein. Equal protein loading was 
verified by re-probing the Western blot membrane with a 
mouse monoclonal anti-β-actin antibody (Sigma-Aldrich, 
Missouri 63103, USA). Densitometric analysis of protein 
bands was performed with the Image J software.
Table 5: Genes used in qRT-PCR (Taqman Low Density Array). * indicates genes used as reference genes for 
normalization.
Gene symbol Gene name (Assay ID) NCBI RefSeq Gene function Assay location 
(amplicon size)
CSNK2A1 Casein kinase 2, alpha 1 
polypeptide (Hs00601957_
m1)
NM_177559.2 Serine/threonine protein 
kinase
169(118)
CSNK2A2 Casein kinase 2, alpha prime 
polypeptide (Hs00176505_
m1)
NM_001896.2 Catalytic subunit alpha’ gene 
of human protein kinase CK2
1213(63)
CSNK2B Casein kinase 2, beta 
polypeptide (Hs00365835_
m1)
NM_001320.5 Beta subunit of human 
protein kinase CK2
413 (83)
HMBS* Hydroxymethylbilane 
synthase (Hs00609297_m1)
NM_000190.3 
NM_001258208.1
Enzyme of heme 
biosynthetic pathway
186 (64) 186(64)
TBP* TATA box binding protein 
(Hs00427621_m1)
NM_001172085.1 
NM_003194.4
Modulates DNA binding 
activity
666(65) 868(65)
PPIA* Peptidylprolyl isomerase A 
(Hs99999904_m1)
NM_021130.3 Cyclosporin binding-protein 433(98)
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Construction of Tissue Micro Arrays
The procedure for construction of TMAs was as 
follows: representative areas of the different lesions 
were carefully selected on H&E stained sections under 
the light microscope and marked on individual paraffin 
blocks. Cores of 3.0 mm were punched from the selected 
contributive paraffin blocks and distributed into 26 new 
blocks including three cores from each tumor and one core 
from each normal renal cortex parenchyma.
Immunohistochemistry
The tissue microarrays were used for 
immunohistochemical staining of CK2α. Immuno 
histochemical staining was performed using Dako 
Powervision (Dako, Denmark A/S) detection system on 
an AutostainerPlus (Dako, Denmark). Briefly, sections of 
3 μm were cut on a microtome and mounted on slides. 
After deparaffination in xylene, slides were driven 
through different grades of ethanol to water, treated 
with 1.5% H2O2 for 10 min to block the endogenous 
peroxidase activity and heated for antigen retrieval in 
TRS buffer (Dako, Denmark A/S) for 15 min. The slides 
were then incubated with the primary rabbit CK2α 
polyclonal antibody for 60 min at a 1:400 dilution and 
incubated with the secondary antibody Poly-HRP anti-
mouse/rabbit IgG (Novocastra PowerVision+Poly-HRP 
IHC Detection Systems, Leica Biosystems) for 30 min. 
Sections were counterstained with Mayer’s hematoxylin 
and visualized with diaminobenzidine (DAB+ chromogen, 
DAKO Denmark, A/S). Slides were afterwards mounted 
automatically with cover films. As positive controls we 
used a multiblock containing different normal tissues, 
among those normal colon, testis and placenta, which 
were used as controls in this study. The negative control 
consisted of omission of the primary antibody.
Evaluation of staining
The stained TMAs were scored separately by 
two pathologists (N.M. and M.R.) in a blinded fashion. 
Semi-quantitative assessment of antibody staining was 
performed using the following score: the extent of staining 
of moderate to strong intensity in the nuclei was scored as 
0 (0%), 1+ (1-25%), 2+(26-50%), 3+(51-75%) or 4+(76-
100%) according to the percentages of the positive staining 
areas relative to the entire core area. The same scoring has 
been previously evaluated and found feasible in previous 
studies on CK2 [16, 47, 48]. The cytoplasm was scored 
as 0 or 1+, when more than 10% of the cytoplasm area 
was positive. A mean score for cytoplasm and nuclei was 
obtained for the three cores from the same patient. The 
sum of scores for nuclei and cytoplasm was used as the 
final CK2α score (0-5+). For statistical purposes, tumors 
with a final staining score of >2+ were considered strongly 
positive for CK2α.
Assessment of VHL mutations
Tissue microarrays were stained for VHL using an 
Autostainer (BenchMark Ultra, Ventana Medical System, 
Tucson, AZ, USA). Sections were blocked for endogenous 
peroxidase activity using H2O2 and treated enzymatically 
with protease 1 for 4 min (760-2018, Ventana Medical 
System, Tucson, AZ, USA) for epitope retrieval. The 
TMAs were then incubated for 32 min at 36°C with the 
primary antibody against VHL (SC-5575, Santa Cruz 
Biotechnology, TX, USA) at a dilution of 1:400. Detection 
and visualization was carried out using OptiView-DAB 
(Ventana Medical System, Tucson, AZ, USA). Sections 
were finally counterstained with hematoxylin (Ventana 
Medical System, Tucson, AZ, USA).
For analysis of expression of VHL, data were 
distributed into two categories: normal (> 10%) vs. altered 
(≤10%) according to the method described by Weber et al 
[49].
Protein kinase assay
The kinase activity of CK2 was performed as 
previously described [50] using a CK2-specific synthetic 
peptide substrate RRRADDSDDDDD and 30 μg whole 
cell lysate.
Cell culture
A cell line established from a primary clear cell 
carcinoma of the kidney, Caki-2 (HTB-47, commercially 
available from American Type Culture Collection (ATCC), 
Rockville, MD) was cultured in McCoy’s 5A medium 
(ATCC, Rockville, MD), supplemented with L-glutamine, 
10% Foetal Bovine Serum (Gibco, Thermo-Fisher, 
Waltham, MA USA) and 1% penicillin/streptomycin 
(Sigma-Aldrich, MO, USA). Cells were cultured 
continuously in a humidified 5% CO2 incubator at 37°C.
Cell proliferation assay
Cell proliferation was spectrophotometrically 
assessed as described previously [51, 52] with some 
modifications. Briefly, Caki-2 cells were seeded at the 
same density (80.000 cells/well) in 12-well plates (flat 
bottom, Costar, Corning Inc. NY, USA) and cultured in 
McCoy’s 5A medium supplemented with L-glutamine, 
with 10% foetal bovine serum and 1% penicillin/
streptomycin, in the presence of CX-4945 (10 μM), E9 
(50 μM) or vehicle (DMSO 0.1% for CX-4945 or DMSO 
0.5% for E9). Final DMSO concentrations were the same 
for each compound and its control. Sterile filtered foetal 
bovine serum served as standard mitogenic stimulus. 
Cells were fixed with formalin (10% in deionized water) 
at days 0,1,2,3,4, and 7 (confluence). Thereafter, cells 
were stained for 10 min with 0.3% Janus B Green dye 
at room temperature under constant stirring. Cells were 
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then de-stained with water and dye was eluted with 0.5 
M HCl at room temperature under constant stirring for 
15 min. Absorbance at 595 nm was determined using a 
microplate reader (Sinergy HT, Biotek, USA). Absorbance 
values correlated with cell density. We performed three 
independent experiments.
Statistical analysis
Comparisons between tumor and renal cortex from 
the same patient were made using the non-parametric 
Wilcoxon signed rank test. Kruskal-Wallis test followed by 
Dunn’s multiple comparisons test was used for analyzing 
differences between more than two groups. Associations 
between the categorical variables were assessed by means 
of the χ2 tests. A p-value <0.05 was considered statistically 
significant. OS (overall survival) was defined as time from 
the date of imaging diagnosis to the date of death from any 
cause or last follow-up contact at any hospital department 
of urology or oncology. DSS (disease specific survival) 
was defined as time from the date of imaging diagnosis 
to the date of death from RCC or last follow-up contact. 
Progression free survival (PFS) was calculated from the 
date of diagnosis by imaging to the date of progression, 
death from any cause or last follow-up contact. Late 
metastasis was defined as metastasis at the time of follow-
up. OS, DSS and PFS in 40 patients with high stage (pT3-
pT4) ccRCC was estimated by the Kaplan Meier method 
and assessed by the log-rank test. Univariate/multivariate 
Cox regression analyses were applied on the same patient 
group. Statistical analysis was carried out using 14.0 
STATA software (StataCorp, Texas, USA).
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